Fig. 3: BET inhibition reduces metastatic UM growth in vivo.
From: Identification of targetable epigenetic vulnerabilities for uveal melanoma
A Experimental outline and timeline of treatments in the metastatic UM mouse model. B Percent survival of mice in each treatment group (n = 10 per group) over the course of 135 days. Median overall survival (MOS) in days of each treatment group is listed. C Bar graph depicting the number of mice in each treatment group with metastatic foci detected in different organs. D Representative histopathological images of kidney, spinal cord (S. cord), liver, and femur metastases from the vehicle-treated group. (* = tumor cells; M = muscle; B = bone; MS = medulla spinalis). E Representative IVIS images of mice in the vehicle and mivebresib treatment groups on day 108. Luminescence/radiance in p/sec/cm2/sr.
